Pranita Tamma, M.D.

Pranita Tamma, M.D.

Institution: Johns Hopkins Univ. School of Medicine

Project: Reducing the Development of Resistance to Anti-Pseudomonal Antibiotics

Grant(s): Innovation Award

Pseudomonas aeruginosa is a bacteria that causes serious infections, often with very poor outcomes in patients with chronic lung conditions such as cystic fibrosis and patients with ventilator dependence. Over time, P. aeruginosa becomes increasingly resistant to commonly used antibiotics. One of three drugs the FDA has recently approved that may have activity against very drug resistant P. aeruginosa is ceftolozane-tazobactam. We have found that for about 20% of patients receiving this antibiotic, their P. aeruginosa became resistant so the antibiotic was no longer effective. We will test patients taking the ceftolozane-tazobactam to understand why these bacteria become resistant to this drug; how often resistance to one drug translates to resistance to one of the other new drugs; and the approaches clinicians can take to limit the emergence of resistance to ceftolozane-tazobactam. Ultimately, we believe that this work will help with future drug development to prevent antibiotic resistance in the treatment of P. aeruginosa.

Transgender Cultural Fluency & LGBTQ+ Lung Health Disparities
, | Jun 14, 2021
A Breath of Knowledge: A Lung Cancer Series for Healthcare Providers and Professionals – Session 4
, | Jun 15, 2021